How Rare Are PSEN1 and PSEN2 Mutations in Early-Onset Alzheimer’s?

PSEN1 explains most mutation-positive dominant early-onset Alzheimer's, PSEN2 very little — and 13% of sporadic cases still carry a mutation.

PSEN1 and PSEN2 mutations are rare in absolute terms but common within a very narrow slice of Alzheimer's disease. PSEN1 — the gene for presenilin 1, a protein that helps cut amyloid precursor protein into the fragments that form plaques — explains an estimated 70–80% of autosomal dominant early-onset cases with a known mutation, while PSEN2 is the rarest of the three main genes.

The arithmetic matters more than the percentages. Early-onset Alzheimer's, meaning symptoms before age 65, is itself only 5–10% of all Alzheimer's, and only about one in ten of those families shows autosomal dominant inheritance — a single faulty copy passed from an affected parent to roughly half their children. So a presenilin mutation carrier is a minority within a minority, which is why population-wide genetic testing has never been the recommendation.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

The numbers, from the widest frame to the narrowest

Start at the top. The 2018 Oncotarget review of early-onset Alzheimer genetics puts early onset at 5–10% of all cases, with roughly 10% of those following an autosomal dominant pattern. Multiply those and you are looking at well under 1% of all Alzheimer's disease. Inside that dominant subset, PSEN1 dominates.

The same review attributes 70–80% of mutation-positive dominant cases to PSEN1, and notes that onset before age 35 is almost entirely PSEN1. PSEN2 trails both PSEN1 and APP, the amyloid precursor protein gene. Measured against whole early-onset cohorts rather than dominant families, the fractions shrink again. A 2019 review in International Journal of Molecular Sciences estimated mutation frequencies in Asian early-onset cohorts at under 1% for APP, about 6% for PSEN1, and about 1% for PSEN2.

Why PSEN2 looks rarer than it may be

Part of PSEN2's rarity is real and part of it is a counting problem. A 2021 systematic ACMG re-evaluation in the Journal of Clinical Medicine assembled 323 reported PSEN1 variants against just 63 for PSEN2 — roughly a five-to-one reporting gap — and found PSEN1 held the most pathogenic or likely-pathogenic variants, followed by APP, then PSEN2. Fewer reported families means weaker estimates.

PSEN2's onset range is also much wider, reported from the 40s into the 80s, so a carrier who develops symptoms at 78 may never be investigated as early-onset at all and never enter these cohorts. Penetrance complicates it further. Penetrance is the share of carriers who actually develop the disease, and it is not always complete: a 22-year follow-up of the PSEN1 H163Y mutation, discussed in Alzheimer's Research & Therapy, showed reduced penetrance even in the gene usually described as near-certain.

A clean family history does not rule a mutation out

This is the finding most likely to change what a family does. Lanoiselée and colleagues screened 129 *sporadic* early-onset cases — people with no affected relatives — and reported in PLOS Medicine that 17 carried PSEN1 mutations and one carried an APP duplication, about 13% of the group. The explanation is new mutations.

In the same study, all 10 carriers whose unaffected parents' DNA was available had *de novo* mutations — arising in that person rather than inherited — including seven PSEN1 missense changes, one splicing variant, one indel, and one in APP. Practically, that means an empty family tree is weak evidence against a presenilin mutation in someone with symptoms starting in their 30s, 40s, or 50s. It also means the mutation can start a new dominant line: a *de novo* carrier's children face the same roughly 50% risk as any inherited case.

What age of onset suggests about which gene

Average onset differs sharply by gene, which is useful context when a clinician is deciding what to test. The 2016 review of the molecular genetics of early-onset Alzheimer's in Alzheimer's & Dementia reports mean symptom onset at 42.9 years for PSEN1 carriers, 51.3 for APP, and 57.1 for PSEN2 — PSEN1 arriving about 8.4 years before APP and 14.2 before PSEN2.

That review also describes PSEN1 penetrance as near-complete by age 60–65. These are means across reported families, not predictions for an individual, and the H163Y follow-up above is a direct reminder that individual carriers deviate. A rough reading of the pattern:.

  • Onset in the 30s or very early 40s with a dominant family history — PSEN1 is by far the likeliest gene.
  • Onset around 50 — APP becomes a realistic alternative.
  • Onset near or after 60 in a dominant family — PSEN2 moves up the list, as does the possibility that no mutation is found.

What testing can and cannot settle

Presenilin testing covers only part of even the dominant subset. NIH's Genetic and Rare Diseases Information Center lists APP, PSEN1, PSEN2, and SORL1 as the known causative genes for early-onset autosomal dominant Alzheimer disease, so a negative PSEN1/PSEN2 result leaves other genes unexamined. Even a full panel often finds nothing.

Campion and colleagues, writing in the American Journal of Human Genetics in 1999, studied 34 French autosomal dominant early-onset families and found PSEN1 missense mutations in 19 (56%) and APP mutations in 5 (15%) — 71% of families — while identifying no PSEN2 mutations at all. The 2019 Asian cohort review put the unexplained share higher still, with roughly 84% of autosomal dominant pedigrees genetically unexplained. So the realistic outcomes of testing are three, not two: a mutation found, a mutation excluded in the genes tested, or — most often, in a dominant family — no answer. Families asking about testing are usually weighing predictive testing in an unaffected relative, which carries insurance, employment, and psychological consequences that differ by country; genetic counseling before the blood draw exists precisely because the "no answer" outcome is the common one and is hard to plan around.

Frequently Asked Questions

If no one in my family had early Alzheimer's, can I still carry a PSEN1 mutation?

Yes. In the PLOS Medicine cohort of 129 sporadic early-onset cases, about 13% carried a causative mutation, and every carrier with testable parents had a new, non-inherited mutation.

Does carrying a PSEN1 mutation guarantee I will develop Alzheimer's?

Penetrance is near-complete by age 60–65 in reported families, but not absolute — the 22-year H163Y follow-up documented reduced penetrance in PSEN1 itself.

Why would a dominant family test negative on all three genes?

Because most do not have a mutation in a known gene. The 2019 Asian cohort review estimated roughly 84% of autosomal dominant pedigrees remain genetically unexplained.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.